You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis
|
|---|---|
| Published in |
Urology, August 2016
|
| DOI | 10.1016/j.urology.2016.07.030 |
| Pubmed ID | |
| Authors |
Ethan L. Matz, Michael H. Hsieh |
| Abstract |
Cyclophosphamide and ifosfamide are widely used drugs for malignancies and rheumatologic conditions. One of the most significant adverse reactions to these drugs is hemorrhagic cystitis (HC). Mesna is the most widely used uroprotective agent that acts to neutralize the caustic metabolite, acrolein, responsible for induction of HC. However, mesna is not a perfect alternative and studies since its discovery have investigated the use of alternative drugs and adjuncts to increase mesna's efficacy. This review details some of the recent work into novel uroprotective agents for drug-induced hemorrhagic cystitis. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| Spain | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 1% |
| Unknown | 96 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 12 | 12% |
| Student > Ph. D. Student | 11 | 11% |
| Researcher | 9 | 9% |
| Student > Bachelor | 8 | 8% |
| Student > Postgraduate | 7 | 7% |
| Other | 21 | 22% |
| Unknown | 29 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 28% |
| Biochemistry, Genetics and Molecular Biology | 11 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 9% |
| Unspecified | 5 | 5% |
| Agricultural and Biological Sciences | 4 | 4% |
| Other | 8 | 8% |
| Unknown | 33 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2017.
All research outputs
#14,915,133
of 25,374,647 outputs
Outputs from Urology
#4,954
of 7,811 outputs
Outputs of similar age
#191,267
of 352,663 outputs
Outputs of similar age from Urology
#82
of 194 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,811 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,663 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 194 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.